HC Wainwright keeps USD 361.00 target for Krystal Biotech stock

Published on 10/15/2026 at 20:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 2, 2026. Krystal Biotech stock costs EUR 295.80 on October 15, 2026, up 0.34 percent on Nasdaq versus its October 14 prior close.

Analyst view and reporting date

HC Wainwright reaffirmed a Buy rating and set a USD 361.00 target on October 15, 2026.
Krystal Biotech is scheduled to report third-quarter results on November 2, 2026.
Krystal Biotech stock costs EUR 295.80 at Lang & Schwarz on October 15, 2026 at 8:29 p.m. CEST, up 0.34 percent on Nasdaq versus the prior close of October 14, 2026.
The company has a USD 9.8 billion market capitalization and a P/E ratio of 41.58.

KRYS, US5011471027, Illustration mit AI erstellt.

HC Wainwright reaffirmed a Buy rating on Krystal Biotech and set a USD 361.00 price target in a report released on October 15, 2026, according to MarketBeat. Against the Nasdaq price of USD 331.82, the target stands 8.80 percent higher. At Lang & Schwarz, the euro quote was EUR 295.80 on October 15, 2026 at 8:29 p.m. CEST; KRYS was up 0.34 percent on Nasdaq versus the prior close of October 14, 2026.

Revenue supports the valuation

Krystal Biotech reported USD 119.22 million in revenue and USD 54.77 million in net income for the second quarter of 2026. Diluted earnings per share were USD 1.79, compared with a USD 1.70 consensus estimate, while revenue trailed the USD 120.93 million forecast, figures reported by MarketBeat show. The mixed comparison leaves product growth and execution central to the valuation.

Stock stays below its yearly high

KRYS traded between USD 183.03 and USD 382.54 over the previous 52 weeks. The latest USD 331.82 price was 13.26 percent below the high and 81.29 percent above the low. Trading volume was 133,966 shares against an average of 370,262.

Valuation and reporting date

Krystal Biotech had a USD 9.8 billion market capitalization and a P/E ratio of 41.58 as of October 15, 2026. The company is scheduled to report third-quarter 2026 results on November 2, 2026, before the US market opens, according to MarketBeat. The consensus calls for USD 127.96 million in revenue and USD 1.85 in earnings per share for that quarter.

Comparison with peers

KRYS (Nasdaq, USD): plus 0.34 percent, P/E 41.58, market capitalization USD 9.8 billion

Vertex Pharmaceuticals (Nasdaq, USD): plus 2.00 percent, P/E 29.60, market capitalization USD 128.9 billion

Relay Therapeutics (Nasdaq, USD): plus 1.73 percent, P/E minus 11.05, market capitalization USD 3.8 billion

Euro quote after hours

Krystal Biotech, Inc. is a biotechnology company focused on genetic medicines for rare diseases and is listed on Nasdaq under KRYS, according to the company's investor-relations page at Krystal Biotech. The latest euro quote places the stock below its USD 382.54 yearly high while the upcoming report provides the next scheduled operating checkpoint. Krystal Biotech stock was trading at EUR 295.80 at Lang & Schwarz on October 15, 2026 at 8:29 p.m. CEST, up 0.34 percent on Nasdaq versus the prior close of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Krystal Biotech stock.